Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Patients on GLP-1 medications for obesity or diabetes are reporting a surprising side effect: drinking less. Clinicians are seeing reduced cravings and fewer heavy-drinking days, backed by small but promising trials. While not yet FDA-approved for alcohol use disorder, GLP-1s are emerging as a compelling off-label tool — with one important safety caveat around withdrawal risk.
Patients taking GLP-1 medications for weight loss or diabetes are reporting an unexpected perk: alcohol just doesn't appeal to them the way it used to. Addiction medicine specialists say patients describe pouring a drink, taking a sip, and walking away — the craving simply neutralized. A nationally representative US survey found that 44% of GLP-1 users who were drinking at the time they started the medication reported drinking less within three months, rising to 54% among those with potentially unhealthy drinking patterns.
Controlled trial data are beginning to back up these anecdotes. Three recent trials of semaglutide — published in JAMA Psychiatry, The Lancet, and the American Journal of Psychiatry — showed reductions in heavy-drinking days and craving, though results varied by endpoint and population. Clinicians emphasize that GLP-1s aren't replacing established treatments like naltrexone, but are being added when standard therapies fall short.
Key Takeaways:
Why it matters: With fewer than 2% of people who could benefit from AUD medications actually taking them, GLP-1s offer a new entry point — and a conversation starter — for clinicians to address alcohol use in patients who might not otherwise seek addiction treatment.
